ImmunityBio, Inc. (IBRX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, ImmunityBio, Inc. (IBRX) trades at a price-to-earnings ratio of -15.8x, with a stock price of $9.78 and trailing twelve-month earnings per share of $-0.37.
Compared to the Healthcare sector median P/E of 23.7x, IBRX trades at a 167% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, IBRX trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IBRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Oncology Therapeutics Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
INCYIncyte Corporation | $20B | 15.8 | - | +4173%Best |
GMABGenmab A/S | $18B | 15.4 | 0.53 | +84% |
EXELExelixis, Inc. | $12B | 15.8 | 0.31Best | +58% |
INBXInhibrx Biosciences, Inc. | $1B | 0.6Lowest | - | +2377% |
BBOTBridgeBio Oncology Therapeutics Inc. | $794M | 21.8 | - | - |
PBYIPuma Biotechnology, Inc. | $287M | 9.3 | - | -2% |
CHRSCoherus Oncology, Inc. | $194M | 6.7 | - | +110% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See IBRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IBRX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IBRX vs AGIO
See how IBRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is IBRX stock overvalued or undervalued?
IBRX current P/E: -15.8x. 5-year average P/E: N/A. Percentile: N/A.
How does IBRX's valuation compare to peers?
ImmunityBio, Inc. P/E of -15.8x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is IBRX's PEG ratio?
IBRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.